Glukoza Fresenius Kabi

Glukoza Fresenius Kabi is an intravenous solution that contains glucose monohydrate as its sole active ingredient. Marketed in the European Union, the product is supplied as a sterile liquid for infusion. It provides a readily available source of carbohydrate and osmotic balance when administered by healthcare professionals in hospital or clinical settings. The formulation is designed for single‑use vials or bags and complies with EU pharmacopeial standards for sterility and purity.

Glukoza Fresenius Kabi is used in clinical practice wherever rapid provision of glucose and fluid volume is required.

- Correction of hypoglycemia in patients unable to take oral carbohydrates. - Supplemental energy source during parenteral nutrition or peri‑operative care. - Maintenance of intravascular volume and osmotic pressure in dehydration or shock. - Dilution and carrier for compatible intravenous medications. - Support during diagnostic procedures such as imaging studies that require glucose infusion. - Provision of a controlled glucose load for metabolic testing or glucose tolerance assessments.

When administered intravenously, Glukoza Fresenius Kabi may be associated with a range of observed effects, most of which are mild and transient.

Common: - Mild hyperglycemia or transient rise in blood glucose levels. - Local irritation or pain at the infusion site. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness during rapid infusion. - Transient flushing or warmth sensation. - Mild increase in serum osmolality. - Temporary change in urine output due to osmotic effect.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic or anaphylactic reaction to the solution. - Electrolyte imbalance, particularly hyponatremia, if large volumes are infused rapidly. - Risk of volume overload in patients with cardiac or renal impairment.

Glukoza Fresenius Kabi should be used with attention to patient‑specific factors and clinical setting to minimize risks and ensure safe administration.

- Assess blood glucose level before and during infusion, especially in diabetic or hypoglycaemic patients. - Adjust infusion rate in patients at risk of fluid overload, such as those with heart failure or renal insufficiency. - Monitor electrolytes, particularly sodium and potassium, when large volumes are administered. - Avoid use in patients with known hypersensitivity to glucose solutions or excipients. - Ensure proper aseptic technique to prevent contamination and catheter‑related infections. - Document infusion parameters and patient response in the medical record.

Glukoza Fresenius Kabi may interact with other intravenous agents or systemic medications; awareness of potential interactions helps maintain therapeutic balance.

Avoid: - Do not mix with calcium‑containing solutions, as precipitation can occur. - Avoid concurrent infusion with high‑dose insulin without glucose monitoring, which may precipitate severe hypoglycaemia. - Do not administer simultaneously with potassium chloride solutions, as high osmolarity may cause vein irritation.

Use with caution: - Co‑administration with diuretics may exacerbate electrolyte shifts; monitor serum electrolytes closely. - Concurrent use with beta‑blockers can mask typical signs of hypoglycaemia; increase glucose monitoring frequency. - When combined with other hyperosmolar solutions, assess total osmolar load to prevent fluid overload.